Unit | Medicines Implementation Research
CARAMAL – Community Access to Rectal Artesunate for Malaria
Many children suffering from severe malaria live in poor rural communities with no access to health care. Where parenteral treatment of severe malaria is not available, the World Health Organization recommends treating children less than 6 years old with a single rectal dose artesunate prior to referral to an appropriate facility where the full package of care for severe malaria can be provided. The CARAMAL study investigates the operational feasibility to introduce rectal artesunate into a functioning severe malaria case management system and generates evidence that will guide the design of appropriate strategies for implementation and scale-up of rectal artesunate.
Artesunate to Treat Severe Malaria
The serious disease malaria is a high burden in tropical and subtropical countries. Although big effort has been done in controlling malaria, it still causes more than 400 000 people each year. Therefore, new treatments are urgently needed. The implementation of the promising drug artesunate is assessed in the MATIAS study.